We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$142M
Cap. Flow %
2.54%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Financials 1.77%
3 Technology 0.15%
4 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
126
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-25,000
Closed -$275K
LLY icon
127
CALL
Eli Lilly
LLY
$1.09T
– –
-100,000
Closed -$4.91M
PBYI icon
128
Puma Biotechnology
PBYI
$399M
– –
-295,000
Closed -$13.1M
PCRX icon
129
Pacira BioSciences
PCRX
$1.04B
– –
-498,000
Closed -$14.4M
PFE icon
130
CALL
Pfizer
PFE
$144B
– –
-3,412,852
Closed -$90.7M
VTRS icon
131
CALL
Viatris
VTRS
$20.7B
– –
-300,000
Closed -$9.31M
XBI icon
132
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-750,000
Closed -$26.1M
ZTS icon
133
Zoetis
ZTS
$32.8B
– –
-131,732
Closed -$4.07M
ONCT
134
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-36
Closed -$330K
SGEN
135
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-200,000
Closed -$6.29M
NTUS
136
DELISTED
Natus Medical Inc
NTUS
– –
-1,427,000
Closed -$19.5M
ACHN
137
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-545,000
Closed -$4.46M
WCG
138
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-500,000
Closed -$27.8M
ECYT
139
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-662,000
Closed -$8.69M
SQNM
140
DELISTED
SEQUENOM INC NEW
SQNM
– –
-3,603,000
Closed -$15.2M
MR
141
DELISTED
MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A
MR
– –
-12,000
Closed -$449K
AUXL
142
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-60,000
Closed -$998K
DNDN
143
CALL
DELISTED
DENDREON CORPORATION
DNDN
– –
-698,900
Closed -$2.88M
HITK
144
DELISTED
HI-TECH PHARMACAL INC
HITK
– –
-371,200
Closed -$12.3M
GIVN
145
DELISTED
GIVEN IMAGING LTD
GIVN
– –
-120,000
Closed -$1.68M
ELN
146
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
– –
-500,000
Closed -$7.07M
MAKO
147
DELISTED
MAKO SURGICAL CORP COM
MAKO
– –
-2,212,100
Closed -$26.7M
OPTR
148
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
– –
-536,000
Closed -$7.76M
ASTX
149
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
– –
-250,000
Closed -$1.03M
ASTX
150
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
– –
-3,256,100
Closed -$13.4M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2013 filing shows 29 new, 38 increased, 31 reduced and 27 closed positions. Its largest new stake was Shire pic: 690,900 shares worth $82.8M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.